Trials / Completed
CompletedNCT02340195
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine following multiple dosing in patients with renal impairment and compare to those in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idalopirdine (Lu AE58054) 60 mg | encapsulated film-coated tablets for oral use once daily for 10 days |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-09-01
- First posted
- 2015-01-16
- Last updated
- 2015-11-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02340195. Inclusion in this directory is not an endorsement.